{"denoms":[{"counts":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"51"},{"groupId":"BG002","value":"105"},{"groupId":"BG003","value":"32"},{"groupId":"BG004","value":"40"},{"groupId":"BG005","value":"236"}],"units":"Participants"}],"groups":[{"description":"Patients undergo surgery and then receive no further treatment.\n\nLaboratory Biomarker Analysis: Correlative studies\n\nTherapeutic Conventional Surgery: Undergo surgery","id":"BG000","title":"Very Low-risk Group"},{"description":"Patients undergo surgery and then receive adjuvant cisplatin IV over 6 hours on day 1, fluorouracil IV over 2-4 minutes on day 2, and vincristine sulfate IV over 1 minute on days 2, 9, and 16. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.\n\nCisplatin: Given IV\n\nFluorouracil: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nTherapeutic Conventional Surgery: Undergo surgery\n\nVincristine Sulfate: Given IV","id":"BG001","title":"Low-risk Group (Regimen T)"},{"description":"Patients receive C5VD chemotherapy comprising cisplatin IV over 6 hours on day 1, fluorouracil IV over 2-4 minutes on day 2, vincristine sulfate IV over 1 minute on days 2, 9, and 16, and doxorubicin hydrochloride IV over 15 minutes on days 1-2. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients also undergo surgical resection after course 2 OR surgical resection or liver transplantation after course 4 of C5VD. Patients may also receive dexrazoxane IV over 5-15 minutes on days 1-2 of courses 5 and 6. (Closed to accrual as of 3/12/2012)\n\nCisplatin: Given IV\n\nDexrazoxane: Given IV\n\nDoxorubicin Hydrochloride: Given IV\n\nFluorouracil: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nLiver Transplantation: Undergo liver transplant\n\nTherapeutic Conventional Surgery: Undergo surgery\n\nVincristine Sulfate: Given IV","id":"BG002","title":"Intermediate-risk Group (Regimen F)"},{"description":"(regimen W replaced by regimen H as of Amendment 3B) Patients receive up front VI chemotherapy comprising vincristine sulfate IV on days 1 and 8 and irinotecan hydrochloride IV over 90 minutes on days 1-5. Treatment with VI repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients with disease response then receive 6 courses of C5VD with 1 courses of VI in between each 2-course block. Patients with no disease response receive 6 courses of C5VD in the absence of disease progression or unacceptable toxicity.\n\nCisplatin: Given IV\n\nDoxorubicin Hydrochloride: Given IV\n\nFluorouracil: Given IV\n\nIrinotecan Hydrochloride: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nTherapeutic Conventional Surgery: Undergo surgery\n\nVincristine Sulfate: Given IV","id":"BG003","title":"High-risk Group (Regimen W)"},{"description":"Patients receive up front VIT chemotherapy comprising vincristine sulfate IV over 1 minute on days 1 and 8 and irinotecan hydrochloride IV over 90 minutes on days 1-5, and temsirolimus IV over 30 minutes on days 1 and 8. Treatment with VIT repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients with disease response then receive 6 courses of C5VD with 4 courses of VIT in between each 2-course block. Patients with no disease response receive 6 courses of C5VD in the absence of disease progression or unacceptable toxicity. Patients undergo tumor resection or liver transplant after course 4 of C5VD followed by 2 courses of adjuvant C5VD. Patients may also receive dexrazoxane IV over 5-15 minutes on days 1-2 of courses 5 and 6.\n\nCisplatin: Given IV\n\nDoxorubicin Hydrochloride: Given IV\n\nFluorouracil: Given IV\n\nIrinotecan Hydrochloride: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nLiver Transplantation: Undergo liver transplant\n\nTemsirolimus: Given IV\n\nTherapeutic Conventional Surgery: Undergo surgery\n\nVincristine Sulfate: Given IV","id":"BG004","title":"High-risk Group (Regimen H)"},{"description":"Total of all reporting groups","id":"BG005","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"51"},{"groupId":"BG002","value":"105"},{"groupId":"BG003","value":"32"},{"groupId":"BG004","value":"40"},{"groupId":"BG005","value":"236"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"2.56","value":"2.5"},{"groupId":"BG001","spread":"1.71","value":"1.59"},{"groupId":"BG002","spread":"2.61","value":"1.42"},{"groupId":"BG003","spread":"2.4","value":"2.31"},{"groupId":"BG004","spread":"2.9","value":"2.75"},{"groupId":"BG005","spread":"2.5","value":"1.84"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"43"},{"groupId":"BG003","value":"12"},{"groupId":"BG004","value":"13"},{"groupId":"BG005","value":"84"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"36"},{"groupId":"BG002","value":"62"},{"groupId":"BG003","value":"20"},{"groupId":"BG004","value":"27"},{"groupId":"BG005","value":"152"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"27"},{"groupId":"BG003","value":"10"},{"groupId":"BG004","value":"16"},{"groupId":"BG005","value":"67"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"35"},{"groupId":"BG002","value":"73"},{"groupId":"BG003","value":"22"},{"groupId":"BG004","value":"23"},{"groupId":"BG005","value":"160"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"9"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"6"},{"groupId":"BG005","value":"22"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"1"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"23"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"29"},{"groupId":"BG002","value":"75"},{"groupId":"BG003","value":"20"},{"groupId":"BG004","value":"25"},{"groupId":"BG005","value":"154"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"15"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"6"},{"groupId":"BG005","value":"36"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"50"},{"groupId":"BG002","value":"98"},{"groupId":"BG003","value":"30"},{"groupId":"BG004","value":"37"},{"groupId":"BG005","value":"223"}]}],"title":"United States"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"7"}]}],"title":"Canada"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"3"}]}],"title":"Australia"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"3"}]}],"title":"Japan"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}]}